BACKGROUND: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. METHODS: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24-h intravenous infusion repeated every 3-4 weeks. RESULTS: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. CONCLUSION: The study paclitaxel regimen was ineffective in refractory adult ALL.
BACKGROUND: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. METHODS:Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24-h intravenous infusion repeated every 3-4 weeks. RESULTS: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. CONCLUSION: The study paclitaxel regimen was ineffective in refractory adult ALL.
Authors: H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: E A Sausville; S G Arbuck; R Messmann; D Headlee; K S Bauer; R M Lush; A Murgo; W D Figg; T Lahusen; S Jaken; X Jing ; M Roberge; E Fuse; T Kuwabara; A M Senderowicz Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: Terzah M Horton; Matthew M Ames; Joel M Reid; Mark D Krailo; Thomas Pendergrass; Revonda Mosher; Gregory H Reaman; Nita L Seibel Journal: Pediatr Blood Cancer Date: 2008-04 Impact factor: 3.167